During the first week after NK:TCR infusion both groups of mice treated with the genetically engineered NK cells (NK:BOB1-TCR and NK:BOB1-TCR/IL-15) demonstrated decrease in tumor burden, however only when mice were treated with NK:BOB1-TCR/IL-15 was the tumor burden significantly decreased in all mice (Figures 5A, B). The gene discussed is IL15; the disease is neoplasm.